Financials

News Discussions Forecast Seasonals

S2P fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to SIMCERE PHARMAC. GRP LTD operating, investing, and financing activities

S2P free cash flow for H1 24 is 111.74 M EUR. For 2023, S2P free cash flow was -5.49 M EUR and operating cash flow was 56.44 M EUR.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: EUR

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—